晚期肝纤维化而非脂肪变与中国2型糖尿病患者白蛋白尿独立相关
该研究纳入香港糖尿病登记处2013年3月至2014年5月招募的1763例中国2型糖尿病患者。瞬时弹性成像检测显示,晚期肝纤维化而非肝脂肪变与白蛋白尿风险独立相关(OR 1.52;95%CI 1.02-2.28;p=0.039),且风险随纤维化严重程度呈剂量依赖增加。
要点
- 在1763例中国2型糖尿病患者中,晚期肝纤维化而非肝脂肪变与白蛋白尿独立相关(OR 1.52;95%CI 1.02-2.28;p=0.039)。
- 白蛋白尿患病率:无NAFLD组41.4% vs 肝脂肪变组46.2% vs 晚期肝纤维化组64.2%(p<0.001)。
- 白蛋白尿风险随肝纤维化严重程度呈剂量依赖增加,LSM≥11.5 kPa(M探头)或≥11.0 kPa(XL探头)者调整后OR 1.53(95%CI 1.07-2.20;p=0.021)。
核心结论
- 晚期肝纤维化而非脂肪变与中国2型糖尿病患者的白蛋白尿独立相关。
- 对于合并白蛋白尿的肥胖和2型糖尿病患者,应关注肝纤维化。
研究设计与样本
- 研究纳入香港糖尿病登记处2013年3月至2014年5月招募的1763例中国2型糖尿病患者。
- 采用瞬时弹性成像进行肝脏硬度测量(LSM,使用探头特异性截断值)检测晚期肝纤维化,并用受控衰减参数(CAP)评估肝脂肪变。
主要发现
- 研究人群平均(标准差)年龄60.7(11.5)岁,糖尿病病程10.8(8.5)年。
- 白蛋白尿患病率在无NAFLD组为41.4%,肝脂肪变组为46.2%,晚期肝纤维化组为64.2%(p<0.001)。
- 在eGFR≥60 ml/min/1.73 m²的患者中,调整糖化血红蛋白、高血压和体重指数等潜在混杂因素后,晚期肝纤维化而非肝脂肪变与白蛋白尿风险增加相关(OR 1.52;95%CI 1.02-2.28;p=0.039)。
- 白蛋白尿的比值比随肝纤维化严重程度呈剂量依赖增加,LSM≥11.5 kPa(M探头)或≥11.0 kPa(XL探头)者调整后OR 1.53(95%CI 1.07-2.20;p=0.021)。
临床怎么用
- 作者认为,对于合并白蛋白尿的肥胖和2型糖尿病患者,应关注肝纤维化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Increasing evidence suggests that non-alcoholic fatty liver disease (NAFLD) may be an independent risk factor for chronic kidney disease (CKD). Given the high prevalence of NAFLD among patients with diabetes who are also at risk of CKD, we aimed to investigate the association between NAFLD and albuminuria, a marker commonly found in diabetic nephropathy. METHODS: This study included a cohort of Chinese patients with type 2 diabetes from the Hong Kong Diabetes Registry recruited between March 2013 and May 2014. Liver stiffness measurement (LSM), with probe-specific cut-offs, was used to detect advanced liver fibrosis. While controlled attenuation parameter (CAP) was used to assess liver steatosis using transient elastography. RESULTS: A total of 1,763 Chinese patients with type 2 diabetes were recruited in this analysis. The mean (standard deviation) age and duration of diabetes were 60.7 (11.5) years and 10.8 (8.5) years, respectively. The prevalence of albuminuria was higher in diabetic patients with liver steatosis and those with advanced fibrosis (no NAFLD vs. liver steatosis vs. advanced fibrosis: 41.4% vs. 46.2% vs. 64.2%, p <0.001). After adjustment for potential confounders including glycated hemoglobin, hypertension and body mass index, advanced fibrosis, but not liver steatosis, was associated with increased risk of albuminuria (odds ratio [OR] 1.52; 95% confidence interval [CI] 1.02-2.28; p = 0.039) in patients with eGFR ≥60 ml/min/1.73 m2. The odds of albuminuria increased with greater severity of liver fibrosis in a dose dependent manner, with the highest odds observed in patients with LSM scores ≥11.5 kPa assessed by M probe or ≥11.0 kPa assessed by XL probe (adjusted OR 1.53; 95% CI 1.07-2.20; p = 0.021). CONCLUSIONS: Advanced liver fibrosis, but not steatosis, is independently associated with albuminuria in Chinese patients with type 2 diabetes. Attention should be paid to liver fibrosis in patients with obesity and type 2 diabetes complicated with albuminuria. LAY SUMMARY: In this study, we assessed the link between non-alcoholic fatty liver disease (NAFLD) and albuminuria in a cohort of 1,763 Chinese patients with type 2 diabetes. This study shows that advanced liver fibrosis, a severe form of NAFLD, was independently associated with increased risk of albuminuria. The risk of albuminuria increased with greater severity of liver fibrosis.
引用
- Yeung MW, Wong GL, Choi KC, et al. Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. J Hepatol. 2017. PMID: 28989092. doi:10.1016/j.jhep.2017.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。